

National Board of Examinations

Question Paper Name :	DNB Radiation Oncology Paper2
Subject Name :	DNB Radiation Oncology Paper2
Creation Date :	2024-10-18 15:26:13
Duration :	180
Total Marks :	100
Display Marks:	No
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DNB Radiation Oncology Paper2

Group Number :	1
Group Id :	3271872827
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Break time :	0
Group Marks :	100

DNB Radiation Oncology Paper2

Section Id :	3271872830
Section Number :	1
Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions :	10
Number of Questions to be attempted :	10
Section Marks :	100
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271872834
Question Shuffling Allowed :	No

Question Number : 1 Question Id : 32718729554 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Role of concurrent chemoradiotherapy for locally advanced oropharyngeal cancer with the available evidence. [3]
- b) Acute and late toxicities of chemoradiation and how to minimize them. [4]
- c) Role of targeted therapy in chemoradiation. [3]

Question Number : 2 Question Id : 32718729555 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) What are the indications for Brachytherapy for Carcinoma prostate? [5]
- b) Which radioisotopes are commonly used for permanent prostate implants and what are their dose recommendations? [3]
- c) Enumerate the side effects of prostate Brachytherapy. [2]

Question Number : 3 Question Id : 32718729556 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Staging and prognostic factors of Wilms' tumour. [4]
- b) Management of Wilms' tumour. [6]

Question Number : 4 Question Id : 32718729557 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

With regard to urinary bladder cancer, discuss:

- a) Staging and workup of carcinoma bladder. [4]
- b) Treatment recommendations for both non-muscle invasive and muscle invasive bladder cancer. [6]

Question Number : 5 Question Id : 32718729558 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

What are the advantages and disadvantages of:

- a) Conventional Radiotherapy. [2]
- b) 3D CRT. [2]
- c) IMRT. [2]
- d) IGRT. [2]
- e) SRT. [2]

Question Number : 6 Question Id : 32718729559 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) What are small round cell tumors? [2]
- b) Enumerate the investigations to differentiate and make a final diagnosis for the entity. [3]
- c) Describe with regard to presentation, diagnosis, management and prognosis of small cell lung cancer. [5]

Question Number : 7 Question Id : 32718729560 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) What are the different therapeutic classes of endocrine manipulation for breast cancer? [5]
- b) How will you select a hormonal agent and why? [3]
- c) What is the ideal duration of hormone therapy in adjuvant and metastatic setting? [2]

Question Number : 8 Question Id : 32718729561 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

Discuss penile carcinoma, with respect to:

- a) Staging of the disease. [5]
- b) Stagewise management. [5]

Question Number : 9 Question Id : 32718729562 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Radiotherapy in elderly patients. [5]
- b) Chemotherapy in elderly patients. [5]

Question Number : 10 Question Id : 32718729563 Question Type : SUBJECTIVE Consider As Subjective : Yes

Correct Marks : 10

- a) Medical versus surgical orchiectomy, indications and guidelines in Oncology. [3]
- b) CDK 4/6 inhibitors. [3]
- c) Options for Targeted therapy in NSCLC stage IIIB. [4]